Jatenzo Cost in Arkansas 2026: Cash Price, Insurance, Medicaid, and Compounded Alternatives

What Is Jatenzo and Why Does Its Price Matter?

Jatenzo is the first FDA-approved oral testosterone undecanoate formulation in the United States, cleared on March 27, 2019, for adult males with hypogonadism caused by conditions such as Klinefelter syndrome, orchidectomy, or primary testicular failure. Unlike older injectable or transdermal testosterone products, Jatenzo is absorbed through the intestinal lymphatic system, which largely bypasses first-pass hepatic metabolism. That mechanism was central to why the FDA approved it: earlier oral testosterone products caused clinically significant liver toxicity, but lymphatic absorption sidesteps that risk. [1]

The Swerdloff et al. key trial (J Clin Endocrinol Metab, 2020, N=166) demonstrated that 87% of treated men achieved average testosterone concentrations (C-avg) within the eugonadal range of 300 to 1 to 000 ng/dL over a 24-hour dosing interval at steady state. [2] That efficacy profile, combined with the oral convenience, makes Jatenzo a meaningful option for men who cannot or will not use injections or gels.

But the drug carries a high list price. At roughly $900 per month, it costs substantially more than generic testosterone cypionate injections (typically $30 to $60 per month at Arkansas pharmacies). Understanding every available cost-reduction pathway in Arkansas is therefore a practical clinical question, not merely a financial one: affordability directly affects whether a patient stays on therapy long enough to see meaningful symptomatic and laboratory benefit. [3]

Testosterone replacement therapy guidelines from the Endocrine Society state that clinicians should "use the preparation that best suits the patient's preferences, pharmacokinetics, and cost" to support long-term adherence. [4]

Jatenzo Cash Price in Arkansas in 2026

The Arkansas retail cash price for a 30-day supply of Jatenzo 237 mg capsules sits at approximately $900 in 2026, consistent with the Tolmar manufacturer list price.

This figure does not meaningfully vary across major Arkansas retail chains because Jatenzo carries no significant generic competition and Tolmar has not published state-specific wholesale price reductions. GoodRx and similar discount aggregators occasionally show prices 5% to 10% below list, but savings in that range do not fundamentally change the affordability calculation for most uninsured patients. A patient paying cash for 12 months of Jatenzo would spend approximately $10,800 annually at list price.

Contrast that with testosterone cypionate 200 mg/mL, which the FDA has approved for hypogonadism and which costs $30 to $60 per month for a 10 mL vial at most Arkansas pharmacies. [5] The cost differential between Jatenzo and injectable testosterone is real and should be documented in shared decision-making conversations.

For patients who specifically require or prefer an oral route, the two practical paths to cost reduction in Arkansas are: (1) insurance coverage with or without manufacturer copay assistance, and (2) compounded oral testosterone undecanoate from a licensed 503A pharmacy. Both are discussed in detail below.

Arkansas Medicaid Coverage for Jatenzo

Arkansas Medicaid (Arkansas DHS Division of Medical Services) covers Jatenzo for male hypogonadism, but only after a prior authorization is approved.

Prior authorization for Jatenzo under Arkansas Medicaid typically requires the prescriber to document a confirmed diagnosis of primary or secondary hypogonadism based on two morning serum testosterone measurements below 300 ng/dL obtained on separate days, consistent with Endocrine Society clinical practice guidelines. [4] The prescriber must also document the specific etiology when possible (e.g., Klinefelter syndrome confirmed on karyotype, bilateral orchidectomy for testicular cancer) because Arkansas Medicaid generally restricts coverage to etiologic hypogonadism rather than age-related testosterone decline alone.

Step therapy requirements may apply. Some Arkansas Medicaid formulary policies require a trial of a lower-cost testosterone formulation, typically generic testosterone cypionate injection, before Jatenzo will be authorized. If the patient has a documented clinical contraindication to injections (needle phobia with documented psychiatric impact, coagulopathy, or severe injection-site reactions), that contraindication can support a first-line Jatenzo PA request.

Processing time for Arkansas Medicaid PA requests is generally 3 to 5 business days for standard reviews and up to 14 days for non-urgent appeals. Patients should not pay out of pocket during a PA review period if their provider has submitted a complete PA request; a temporary supply may be dispensed at pharmacy discretion in some circumstances. [6]

Medicaid beneficiaries who are denied coverage may appeal through the Arkansas DHS fair hearing process. Data from the Kaiser Family Foundation indicate that PA denial appeal success rates for hormone therapies nationally average approximately 40%, meaning a well-documented appeal has a meaningful chance of reversal. [7]

Commercial Insurance Coverage for Jatenzo in Arkansas

Most commercial insurance plans sold in Arkansas, including Blue Cross and Blue Shield of Arkansas, QualChoice, and employer self-insured plans administered by national PBMs like CVS Caremark and Express Scripts, place Jatenzo on a non-preferred specialty tier.

Non-preferred specialty placement generally means the patient pays a percentage coinsurance (often 30% to 50%) rather than a flat copay, and a prior authorization is required. At 30% coinsurance on a $900 list price, a patient pays $270 per month before any manufacturer assistance. At 50%, the out-of-pocket cost reaches $450 per month before assistance.

The Tolmar manufacturer savings card can reduce that cost significantly for eligible commercially insured patients. See the dedicated section below for details.

Patients with Arkansas Marketplace (ACA exchange) plans should check their specific plan's formulary via the healthcare.gov plan comparison tool before assuming coverage. Testosterone products classified as treatments for age-related decline rather than pathologic hypogonadism may be excluded under some ACA plan benefit designs, which track preventive versus therapeutic coverage distinctions. [8] A documented diagnosis code of E29.1 (testicular hypofunction, primary) or E23.0 (hypopituitarism, secondary hypogonadism) supports medical necessity more strongly than a diagnosis code for age-related testosterone decline. [9]

The Tolmar Savings Card: How It Works in Arkansas

Tolmar, the manufacturer of Jatenzo, operates a commercially sponsored savings program that can reduce the monthly out-of-pocket cost to as low as $0 for eligible patients with commercial insurance.

Key eligibility rules as of 2025 to 2026:

• The patient must have commercial insurance that covers Jatenzo (even partially). Cash-pay patients and those covered by federal programs including Medicare, Medicaid, TRICARE, or VA benefits are not eligible.
• The savings card covers the gap between insurance payment and the patient's copay or coinsurance, up to a per-month cap set by Tolmar.
• There is an annual maximum benefit. Once the patient reaches that cap, standard coinsurance applies for the remainder of the calendar year.
• The card is activated through the Tolmar patient services portal or by calling the number on the prescriber's Jatenzo starter kit.

Arkansas-based patients should confirm current savings card terms directly with Tolmar before relying on any specific dollar figure, because copay assistance program terms change at the start of each calendar year. [10] Patients whose plans have a high-deductible structure may find that the savings card does not cover the full deductible phase, depending on how the PBM processes the claim.

Medicare Part D beneficiaries are ineligible for the manufacturer savings card under federal law. Those patients should ask their pharmacist about the Extra Help / Low Income Subsidy program administered through the Social Security Administration, which can reduce Part D cost-sharing across all covered medications including specialty tiers. [11]

Compounded Oral Testosterone Undecanoate in Arkansas: Legality and Cost

Licensed 503A compounding pharmacies in Arkansas may legally prepare oral testosterone undecanoate capsules for individual patients who have a valid prescription from a licensed prescriber.

The legal framework is important to understand clearly. Section 503A of the Federal Food, Drug, and Cosmetic Act permits traditional compounding pharmacies to prepare customized drug preparations for individual patients based on a prescriber's prescription, provided the preparation uses a bulk active pharmaceutical ingredient (API) that appears on FDA's list of bulk substances that may be used in compounding. Testosterone is included on that list. [12] Arkansas state pharmacy law does not prohibit 503A pharmacies from compounding testosterone formulations. [13]

This is legally and practically different from purchasing a non-FDA-approved testosterone product from an unregistered online vendor, which carries significant risk of adulteration and is not legal.

The clinical tradeoffs are real. Compounded oral testosterone undecanoate preparations have not undergone the same pharmacokinetic validation as FDA-approved Jatenzo. The Swerdloff et al. 2020 trial that established Jatenzo's efficacy used a specific self-emulsifying drug delivery system (SEDDS) lipid formulation that enables consistent lymphatic absorption. [2] A compounded capsule using raw testosterone undecanoate powder in a simple lipid base may or may not achieve equivalent bioavailability. Prescribers and patients should discuss this limitation explicitly. Some compounding pharmacies use validated lipid-based formulations that more closely approximate Jatenzo's delivery system, and prescribers may wish to request a certificate of analysis (COA) and formulation details from the compounding pharmacy before prescribing.

Cost for compounded oral testosterone undecanoate at Arkansas 503A pharmacies varies by pharmacy and by formulation, but many patients report costs in the range of $80 to $200 per month, representing savings of $700 to $820 per month compared to Jatenzo list price. For a patient who cannot use the Tolmar savings card and does not have insurance coverage, this cost difference is clinically significant because it directly affects adherence. [14]

The HealthRX Arkansas Cost-Reduction Decision Framework for Oral Testosterone

Use this sequence when evaluating a new Jatenzo patient in Arkansas:

1. Confirm diagnosis: two morning testosterone levels <300 ng/dL on separate days, with documented etiology where possible. [4]
2. Check insurance formulary status. If covered with PA, submit PA with ICD-10 E29.1 or E23.0 and supporting labs.
3. If commercial insurance covers Jatenzo (even partially), activate the Tolmar savings card. Estimated patient cost: $0 to $270/month depending on plan structure.
4. If Arkansas Medicaid, submit PA with step therapy documentation. If step therapy is required, document contraindication to injections if applicable.
5. If patient is uninsured, Medicare, or savings-card-ineligible: evaluate compounded oral TU from a licensed Arkansas 503A pharmacy. Request COA and lipid formulation details. Monitor with morning serum testosterone at 3 to 6 weeks post-titration.
6. If compounded TU is chosen, set explicit follow-up labs. The FDA-approved Jatenzo label specifies checking serum testosterone 6 hours post-dose at steady state (after at least 7 days on current dose) for titration decisions. Apply the same monitoring principle to compounded formulations. [1]

Telehealth Prescribing of Jatenzo in Arkansas

Jatenzo can be prescribed via telehealth in Arkansas.

Arkansas law permits controlled substance prescribing via telemedicine when the prescriber holds an active Arkansas DEA registration and has established a valid patient-prescriber relationship, which may include a synchronous audio-visual visit. Testosterone is a Schedule III controlled substance under the Controlled Substances Act. [15] The Ryan Haight Online Pharmacy Consumer Protection Act requires at least one in-person medical evaluation before a controlled substance may be prescribed via the internet in most circumstances, though the DEA's 2023 proposed rules on telemedicine prescribing of controlled substances have created ongoing regulatory flux; prescribers should verify current requirements with the DEA and Arkansas State Medical Board before prescribing testosterone via telemedicine for a new patient. [16]

HealthRX clinicians operating in Arkansas follow the current DEA guidance and Arkansas State Medical Board telemedicine rules, which as of 2025 permit audio-visual telehealth visits to satisfy the prescribing evaluation requirement for Schedule III substances when no prior in-person visit has occurred, subject to federal rules in effect at the time of prescribing.

Patients initiating Jatenzo via HealthRX telehealth in Arkansas will receive a prescription sent electronically to a pharmacy of their choice, including mail-order pharmacies that may offer modest additional savings over retail pricing. [17]

Monitoring Requirements That Affect Total Jatenzo Cost in Arkansas

The cost of Jatenzo is not limited to the drug's sticker price. Ongoing laboratory monitoring adds to the total out-of-pocket burden for Arkansas patients, especially those on high-deductible plans.

The FDA-approved Jatenzo prescribing information recommends checking:

• Serum testosterone (morning, 6 hours post-dose) at steady state after each dose titration, then periodically during maintenance therapy. [1]
• Hematocrit at baseline and 3 to 6 months after starting therapy, then annually, because testosterone therapy can increase erythrocytosis. The FDA label specifies withholding therapy if hematocrit exceeds 54%. [1]
• Blood pressure at each clinical visit, because Jatenzo can raise systolic blood pressure by a mean of 3 to 5 mmHg in clinical trials; the FDA added a black-box warning noting that Jatenzo is not recommended in men with uncontrolled hypertension. [1]
• Prostate-specific antigen (PSA) at baseline and per the American Urological Association guidelines for prostate health monitoring in men on testosterone therapy. [18]

A typical monitoring panel, including testosterone, hematocrit, comprehensive metabolic panel, and PSA, costs approximately $150 to $400 at Arkansas outpatient lab draws without insurance. Patients with insurance pay their cost-sharing amount. Factoring in two to four monitoring visits per year, the total annual cost of Jatenzo therapy in Arkansas for an uninsured patient could reach $11,400 to $12,400 per year at list price, reinforcing the importance of either insurance coverage or the compounded alternative.

Blood Pressure: The Safety Factor With Direct Cost Implications

The Jatenzo black-box warning on blood pressure is not just a safety footnote. It has direct cost implications for Arkansas patients.

The Swerdloff et al. 2020 study reported a mean increase in systolic blood pressure of approximately 3.9 mmHg in the treated group. [2] The FDA label states: "Jatenzo can cause blood pressure increases that can increase the risk of major adverse cardiovascular events (MACE), including non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death." [1]

Arkansas has one of the highest rates of hypertension prevalence in the United States, with approximately 40.3% of Arkansas adults having diagnosed hypertension as of the most recent CDC Behavioral Risk Factor Surveillance System data. [19] Prescribers should obtain a baseline blood pressure at initiation and recheck at each follow-up. If systolic blood pressure rises above 140 mmHg on Jatenzo, dose reduction or discontinuation should be considered before titrating upward based on testosterone levels alone.

Men who develop treatment-requiring hypertension on Jatenzo face an additional monthly medication cost. First-line antihypertensives such as amlodipine 5 mg run $10 to $15 per month generic in Arkansas, but that is still an added cost layer patients should understand before starting therapy. [20]

Comparing Jatenzo to Other Testosterone Formulations Available in Arkansas

Jatenzo is one of several testosterone formulations legally available in Arkansas. The choice of formulation affects both cost and monitoring burden.

| Formulation | Approximate Arkansas Cash Price | Route | Dosing Frequency | |---|---|---|---| | Testosterone cypionate injection (generic) | $30-$60/month | IM or SubQ | Weekly or biweekly | | Testosterone enanthate injection (generic) | $30-$60/month | IM | Weekly or biweekly | | Testosterone gel 1% (generic) | $50-$100/month | Topical | Daily | | Jatenzo 237 mg (brand) | ~$900/month | Oral | Twice daily with meals | | Compounded oral TU (503A) | $80-$200/month | Oral | Twice daily with meals | | Testosterone pellets (compounded) | $300-$600/insertion | SubQ implant | Every 3-6 months |

Generic injectable testosterone products maintain a strong clinical evidence base. The Endocrine Society clinical practice guidelines for male hypogonadism endorse multiple formulations as clinically equivalent in achieving eugonadal testosterone targets when properly titrated. [4] For patients who place high value on oral administration and have insurance coverage that makes Jatenzo affordable, it remains a reasonable first-line choice. For uninsured or underinsured patients, generic injectables represent an 88% to 97% cost reduction relative to Jatenzo's list price. [21]

Steps to Get Jatenzo Covered in Arkansas: A Prescriber Checklist

Securing insurance coverage for Jatenzo in Arkansas requires accurate documentation from the first submission. Incomplete PA requests are the most common cause of avoidable delays.

A complete Jatenzo PA submission in Arkansas should include:

• Two separate morning serum testosterone lab results (before 10 a.m., fasting preferred) both <300 ng/dL, collected at least one week apart [4]
• ICD-10 diagnosis code E29.1 (primary testicular failure) or E23.0 (hypogonadotropic hypogonadism) or the specific underlying condition code (e.g., Q98.0 for Klinefelter syndrome with 47,XXY karyotype)
• Documentation of etiology (lab results, imaging, surgical records as applicable)
• Clinical justification for oral route preference over lower-cost alternatives, or documented failure of or contraindication to generic injectable testosterone
• Prescriber DEA and Arkansas state license numbers
• Requested duration of coverage (12 months is standard for maintenance PA requests)

When prior authorization is denied, the appeals process begins with a peer-to-peer review request, in which the prescriber speaks directly with the plan's medical director. Published data suggest peer-to-peer reviews overturn initial denials in approximately 50% of cases for specialty medications. [22] If peer-to-peer review fails, a formal written appeal citing clinical necessity and the Endocrine Society guideline language supporting oral testosterone as an endorsed treatment option represents the next step. [4]

The Endocrine Society's 2018 guidelines state directly: "We recommend testosterone therapy for men with hypogonadism to induce and maintain secondary sex characteristics and correct symptoms." [4] That guideline language, cited by name and year in an appeal letter, anchors the medical necessity argument to a named authoritative source.